<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03257098</url>
  </required_header>
  <id_info>
    <org_study_id>allo-APZ2-CVU-II-01</org_study_id>
    <nct_id>NCT03257098</nct_id>
  </id_info>
  <brief_title>Allogeneic ABCB5-positive Stem Cells for Treatment of CVU</brief_title>
  <official_title>An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Chronic Venous Ulcer (CVU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RHEACELL GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ticeba GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Granzer Regulatory Consulting &amp; Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RHEACELL GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size&#xD;
      reduction of Chronic Venous Ulcers) and safety (by monitoring adverse events) of the&#xD;
      medicinal product to be studied after two applications on the wound surface in patients with&#xD;
      Chronic Venous Ulcers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, single arm, phase I/IIa clinical trial to investigate the efficacy&#xD;
      and safety of allogeneic ABCB5-positive mesenchymal stem cells (MSCs) on wound healing in&#xD;
      patients with chronic venous ulcer (CVU). Allogeneic MSCs will be isolated ex vivo and will&#xD;
      be expanded in vitro. The IMP incorporating the ABCB5-positive MSCs will then be applied on&#xD;
      the wound surface of CVU under local anesthesia (on Day 0 and Week 6.1).&#xD;
&#xD;
      Wound measurements from Visit (V) 2 and V9 will be used to determine the cell amount for the&#xD;
      IMP treatments on V3 and V10, respectively.&#xD;
&#xD;
      Patients are followed up for efficacy for 3 months which allows to distinguish actual wound&#xD;
      healing from transient wound coverage.&#xD;
&#xD;
      The wound healing process will be documented by standardized photography. The wound size&#xD;
      evaluation will start on the day of the first change of wound dressing. The quality of the&#xD;
      wound healing process will be assessed on the basis of formation of granulation tissue,&#xD;
      epithelialization and wound exudation.&#xD;
&#xD;
      Pain will be assessed using a numerical rating scale and quality of life will be investigated&#xD;
      with standardized and validated questionnaires. To assess long-term safety of allo-APZ2-CVU&#xD;
      three follow-up visits at Months 6, 9 and 12 after the first IMP applications are included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">June 25, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Interventional, single arm, multicenter, phase I/IIa clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of wound size reduction</measure>
    <time_frame>Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing</time_frame>
    <description>Percentage of wound size reduction at Week 12, or last available post-baseline measurement of Weeks 6, 8 or 10 if the Week 12 measurement is missing (last observation carried forward [LOCF]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse event (AE) occurrence</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>All AEs occurring during the clinical trial will be registered, documented and evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of wound size reduction</measure>
    <time_frame>Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12 (without LOCF);</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute wound size reduction</measure>
    <time_frame>Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving complete wound closure</measure>
    <time_frame>Weeks 2, 3, 4, 6, 8, 10, 12, and at any time point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first complete wound closure</measure>
    <time_frame>A priori specification not possible; between baseline and week 12 post baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving 30% wound closure</measure>
    <time_frame>Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, 12, and at any time point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first 30% wound closure</measure>
    <time_frame>A priori specification not possible; between baseline and week 12 post baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epithelialization</measure>
    <time_frame>Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of further wound healing parameters: formation of granulation tissue and wound exudation</measure>
    <time_frame>Visit 3 and Visit 10 before IMP application, Days 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.2, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment as per numerical rating scale (NRS)</measure>
    <time_frame>Days 0, 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire</measure>
    <time_frame>Day 0 and Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire</measure>
    <time_frame>Day 0 and Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination and vital signs at Week 6.1 and Week 12</measure>
    <time_frame>Week 6.1 and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Skin Ulcer Venous Stasis Chronic</condition>
  <arm_group>
    <arm_group_label>allo-APZ2-CVU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of IMP on patients wound</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allo-APZ2-CVU</intervention_name>
    <description>Suspension of ABCB5-positive mesenchymal stem cells</description>
    <arm_group_label>allo-APZ2-CVU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged 35 to 85 years;&#xD;
&#xD;
          2. Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy resistant&#xD;
             ulcer that shows no improvement within 3 months despite of optimal phlebological&#xD;
             therapies or is not healed within 12 months) diagnosed by doppler ultrasonography&#xD;
             (DUS), ankle brachial index (ABI, 0.9-1.3), physical examination and dermatological&#xD;
             review;&#xD;
&#xD;
          3. Wound size of target ulcer between 1.5 and 100 cm2 measured by a standardized&#xD;
             photography at the screening visits (Visit 1 and Visit 2);&#xD;
&#xD;
          4. Wound location below knee;&#xD;
&#xD;
          5. If patients are suffering from 2 or more ulcers at the same extremity, the target&#xD;
             ulcer has to be separated by a minimum bridge of 1 cm of epithelialized skin from&#xD;
             other ulcers (the largest ulcer should be the target ulcer, if not decided otherwise&#xD;
             at discretion of the investigator; the target ulcer is defined at Visit 1);&#xD;
&#xD;
          6. Body mass index (BMI) between 20 and 45 kg/m²;&#xD;
&#xD;
          7. Patients understand the nature of the procedure and are providing written informed&#xD;
             consent prior to any clinical trial procedure;&#xD;
&#xD;
          8. Women of childbearing potential must have a negative blood pregnancy test at Visit 1&#xD;
&#xD;
          9. Women of childbearing potential and their partner must be willing to use highly&#xD;
             effective contraceptive methods during the course of the clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;&#xD;
&#xD;
          2. Current use of systemic steroid medication above Cushing threshold dose (&gt;7.5 mg/d&#xD;
             prednisone or equivalent);&#xD;
&#xD;
          3. Diabetes mellitus that has to be evaluated by blood test (Haemoglobin A1c [HbA1c]&#xD;
             &gt;7.5%);&#xD;
&#xD;
          4. Peripheral Artery Disease (PAD) including claudication with need of treatment;&#xD;
&#xD;
          5. Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep&#xD;
             vein thrombosis;&#xD;
&#xD;
          6. Unable to tolerate leg ulcer compression bandage;&#xD;
&#xD;
          7. Infection of the target ulcer requiring treatment as judged clinically;&#xD;
&#xD;
          8. Any chronic dermatological disorders diagnosed at the investigator's discretion;&#xD;
&#xD;
          9. Skin disorders, unrelated to the ulcer, that are present adjacent to the target wound;&#xD;
&#xD;
         10. Current use of medications that influence wound healing: systemic immunosuppressives,&#xD;
             cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);&#xD;
&#xD;
         11. Known abuse of alcohol, drugs, or medicinal products;&#xD;
&#xD;
         12. Cancerous or pre-cancerous lesions adjacent to the target wound;&#xD;
&#xD;
         13. Patients anticipated to be unwilling or unable to comply with the requirements of the&#xD;
             protocol;&#xD;
&#xD;
         14. Pregnant or lactating women;&#xD;
&#xD;
         15. Systemic infectious disease diagnosed by serology testing human immunodeficiency virus&#xD;
             (HIV˗1, HIV-2);&#xD;
&#xD;
         16. Any known allergies to components of the IMP;&#xD;
&#xD;
         17. Prior surgical procedures such as bypass or mesh-graft treatment within 2 months prior&#xD;
             to Visit 1;&#xD;
&#xD;
         18. Patients with significant ulcer healing or wound size enlargement of more than 25% at&#xD;
             Visit 2 compared to Visit 1;&#xD;
&#xD;
         19. Treatment of target ulcer with active wound care agents (e.g. iruxol, local&#xD;
             antibiotics or silver dressings), which have not been paused 14 days before IMP&#xD;
             application;&#xD;
&#xD;
         20. Current or previous (within 30 days of enrollment) treatment with another IMP, or&#xD;
             participation and/or under follow-up in another clinical trial;&#xD;
&#xD;
         21. Previous participation in this clinical trial (except for screening failures due to an&#xD;
             inclusion or exclusion criterion);&#xD;
&#xD;
         22. Evidence of any other medical conditions (such as psychiatric illness, physical&#xD;
             examination, or laboratory findings) that may interfere with the planned treatment,&#xD;
             affect the patient's compliance, or place the patient at high risk of complications&#xD;
             related to the treatment;&#xD;
&#xD;
         23. Employees of the sponsor, or employees or relatives of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Kerstan, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum im St. Maria Hilf Krankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>44805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Hautklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Hautkrankheiten, Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg GmbH, Dermatologie / Allergologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>pro scientia med im Mare Klinikum; Department Klinische Forschung und Entwicklung</name>
      <address>
        <city>Kiel</city>
        <zip>24119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Venous Ulcer</keyword>
  <keyword>ABCB5</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>varicose ulcer</keyword>
  <keyword>skin ulcer</keyword>
  <keyword>advanced therapy medicinal product</keyword>
  <keyword>somatic cell therapy</keyword>
  <keyword>phase I/IIa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Skin Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03257098
org study id: allo-APZ2-CVU-II-01
nct id: NCT03257098
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size
      reduction of Chronic Venous Ulcers) and safety (by monitoring adverse events) of the
      medicinal product to be studied after two applications on the wound surface in patients with
      Chronic Venous Ulcers.
This is an interventional, single arm, phase I/IIa clinical trial to investigate the efficacy
      and safety of allogeneic ABCB5-positive mesenchymal stem cells (MSCs) on wound healing in
      patients with chronic venous ulcer (CVU). Allogeneic MSCs will be isolated ex vivo and will
      be expanded in vitro. The IMP incorporating the ABCB5-positive MSCs will then be applied on
      the wound surface of CVU under local anesthesia (on Day 0 and Week 6.1).

      Wound measurements from Visit (V) 2 and V9 will be used to determine the cell amount for the
      IMP treatments on V3 and V10, respectively.

      Patients are followed up for efficacy for 3 months which allows to distinguish actual wound
      healing from transient wound coverage.

      The wound healing process will be documented by standardized photography. The wound size
      evaluation will start on the day of the first change of wound dressing. The quality of the
      wound healing process will be assessed on the basis of formation of granulation tissue,
      epithelialization and wound exudation.

      Pain will be assessed using a numerical rating scale and quality of life will be investigated
      with standardized and validated questionnaires. To assess long-term safety of allo-APZ2-CVU
      three follow-up visits at Months 6, 9 and 12 after the first IMP applications are included.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Interventional, single arm, multicenter, phase I/IIa clinical trial
primary purpose: Treatment
masking: None (Open Label)
measure: Percentage of wound size reduction
time frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing
description: Percentage of wound size reduction at Week 12, or last available post-baseline measurement of Weeks 6, 8 or 10 if the Week 12 measurement is missing (last observation carried forward [LOCF]).
measure: Assessment of adverse event (AE) occurrence
time frame: Up to 12 months
description: All AEs occurring during the clinical trial will be registered, documented and evaluated.
measure: Percentage of wound size reduction
time frame: Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12 (without LOCF);
measure: Absolute wound size reduction
time frame: Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12
measure: Proportion of patients achieving complete wound closure
time frame: Weeks 2, 3, 4, 6, 8, 10, 12, and at any time point
measure: Time to first complete wound closure
time frame: A priori specification not possible; between baseline and week 12 post baseline
measure: Proportion of patients achieving 30% wound closure
time frame: Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, 12, and at any time point
measure: Time to first 30% wound closure
time frame: A priori specification not possible; between baseline and week 12 post baseline
measure: Epithelialization
time frame: Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12
measure: Assessment of further wound healing parameters: formation of granulation tissue and wound exudation
time frame: Visit 3 and Visit 10 before IMP application, Days 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.2, 8, 10, and 12
measure: Pain assessment as per numerical rating scale (NRS)
time frame: Days 0, 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12
measure: Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire
time frame: Day 0 and Weeks 4, 8 and 12
measure: Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire
time frame: Day 0 and Weeks 4, 8 and 12
measure: Physical examination and vital signs at Week 6.1 and Week 12
time frame: Week 6.1 and Week 12
arm group label: allo-APZ2-CVU
arm group type: Experimental
description: Application of IMP on patients wound
intervention type: Biological
intervention name: allo-APZ2-CVU
description: Suspension of ABCB5-positive mesenchymal stem cells
arm group label: allo-APZ2-CVU
criteria: 
gender: All
minimum age: 35 Years
maximum age: 85 Years
healthy volunteers: No
last name: Andreas Kerstan, Dr.
role: Principal Investigator
affiliation: Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Germany
responsible party type: Sponsor
mesh term: Varicose Ulcer
mesh term: Skin Ulcer
mesh term: Ulcer
sharing ipd: No